281 related articles for article (PubMed ID: 32366905)
21. BET bromodomain proteins are required for glioblastoma cell proliferation.
Pastori C; Daniel M; Penas C; Volmar CH; Johnstone AL; Brothers SP; Graham RM; Allen B; Sarkaria JN; Komotar RJ; Wahlestedt C; Ayad NG
Epigenetics; 2014 Apr; 9(4):611-20. PubMed ID: 24496381
[TBL] [Abstract][Full Text] [Related]
22. The BRD4-NUT Fusion Alone Drives Malignant Transformation of NUT Carcinoma.
Durall RT; Huang J; Wojenski L; Huang Y; Gokhale PC; Leeper BA; Nash JO; Ballester PL; Davidson S; Shlien A; Sotirakis E; Bertaux F; Dubus V; Luo J; Wu CJ; Keskin DB; Eagen KP; Shapiro GI; French CA
Cancer Res; 2023 Dec; 83(23):3846-3860. PubMed ID: 37819236
[TBL] [Abstract][Full Text] [Related]
23. Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains.
Reynoird N; Schwartz BE; Delvecchio M; Sadoul K; Meyers D; Mukherjee C; Caron C; Kimura H; Rousseaux S; Cole PA; Panne D; French CA; Khochbin S
EMBO J; 2010 Sep; 29(17):2943-52. PubMed ID: 20676058
[TBL] [Abstract][Full Text] [Related]
24. Novel BRD4-NUT fusion isoforms increase the pathogenic complexity in NUT midline carcinoma.
Thompson-Wicking K; Francis RW; Stirnweiss A; Ferrari E; Welch MD; Baker E; Murch AR; Gout AM; Carter KW; Charles AK; Phillips MB; Kees UR; Beesley AH
Oncogene; 2013 Sep; 32(39):4664-74. PubMed ID: 23128391
[TBL] [Abstract][Full Text] [Related]
25. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells.
French CA; Ramirez CL; Kolmakova J; Hickman TT; Cameron MJ; Thyne ME; Kutok JL; Toretsky JA; Tadavarthy AK; Kees UR; Fletcher JA; Aster JC
Oncogene; 2008 Apr; 27(15):2237-42. PubMed ID: 17934517
[TBL] [Abstract][Full Text] [Related]
26. miR-766-5p Targets Super-Enhancers by Downregulating CBP and BRD4.
Gen Y; Muramatsu T; Inoue J; Inazawa J
Cancer Res; 2021 Oct; 81(20):5190-5201. PubMed ID: 34353856
[TBL] [Abstract][Full Text] [Related]
27. Structural mechanism of BRD4-NUT and p300 bipartite interaction in propagating aberrant gene transcription in chromatin in NUT carcinoma.
Yu D; Liang Y; Kim C; Jaganathan A; Ji D; Han X; Yang X; Jia Y; Gu R; Wang C; Zhang Q; Cheung KL; Zhou MM; Zeng L
Nat Commun; 2023 Jan; 14(1):378. PubMed ID: 36690674
[TBL] [Abstract][Full Text] [Related]
28. Cell state-dependent chromatin targeting in NUT carcinoma.
Alekseyenko AA; Zee BM; Dhoondia Z; Kang H; Makofske JL; Kuroda MI
Genetics; 2023 Jul; 224(3):. PubMed ID: 37119804
[TBL] [Abstract][Full Text] [Related]
29. Complex chromosomal rearrangements by single catastrophic pathogenesis in NUT midline carcinoma.
Lee JK; Louzada S; An Y; Kim SY; Kim S; Youk J; Park S; Koo SH; Keam B; Jeon YK; Ku JL; Yang F; Kim TM; Ju YS
Ann Oncol; 2017 Apr; 28(4):890-897. PubMed ID: 28203693
[TBL] [Abstract][Full Text] [Related]
30. New developments in the molecular pathogenesis of head and neck tumors: a review of tumor-specific fusion oncogenes in mucoepidermoid carcinoma, adenoid cystic carcinoma, and NUT midline carcinoma.
Bhaijee F; Pepper DJ; Pitman KT; Bell D
Ann Diagn Pathol; 2011 Feb; 15(1):69-77. PubMed ID: 21238915
[TBL] [Abstract][Full Text] [Related]
31. Differentiation of NUT midline carcinoma by epigenomic reprogramming.
Schwartz BE; Hofer MD; Lemieux ME; Bauer DE; Cameron MJ; West NH; Agoston ES; Reynoird N; Khochbin S; Ince TA; Christie A; Janeway KA; Vargas SO; Perez-Atayde AR; Aster JC; Sallan SE; Kung AL; Bradner JE; French CA
Cancer Res; 2011 Apr; 71(7):2686-96. PubMed ID: 21447744
[TBL] [Abstract][Full Text] [Related]
32. NUT Carcinoma: Clinicopathologic features, pathogenesis, and treatment.
French CA
Pathol Int; 2018 Nov; 68(11):583-595. PubMed ID: 30362654
[TBL] [Abstract][Full Text] [Related]
33. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
[TBL] [Abstract][Full Text] [Related]
34. The Oncoprotein BRD4-NUT Generates Aberrant Histone Modification Patterns.
Zee BM; Dibona AB; Alekseyenko AA; French CA; Kuroda MI
PLoS One; 2016; 11(10):e0163820. PubMed ID: 27698495
[TBL] [Abstract][Full Text] [Related]
35. NUT midline carcinoma: an aggressive intrathoracic neoplasm.
Parikh SA; French CA; Costello BA; Marks RS; Dronca RS; Nerby CL; Roden AC; Peddareddigari VG; Hilton J; Shapiro GI; Molina JR
J Thorac Oncol; 2013 Oct; 8(10):1335-8. PubMed ID: 24457244
[TBL] [Abstract][Full Text] [Related]
36. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
37. The first report of molecular characterized BRD4-NUT carcinoma in Brazil: a case report.
Oliveira LJC; Gongora ABL; Latancia MT; Barbosa FG; Gregorio JVAM; Testagrossa LA; Amano MT; Feher O
J Med Case Rep; 2019 Sep; 13(1):279. PubMed ID: 31492174
[TBL] [Abstract][Full Text] [Related]
38. Comparative drug screening in NUT midline carcinoma.
Beesley AH; Stirnweiss A; Ferrari E; Endersby R; Howlett M; Failes TW; Arndt GM; Charles AK; Cole CH; Kees UR
Br J Cancer; 2014 Mar; 110(5):1189-98. PubMed ID: 24518598
[TBL] [Abstract][Full Text] [Related]
39. Bromodomain protein BRD4 promotes cell proliferation in skin squamous cell carcinoma.
Xiang T; Bai JY; She C; Yu DJ; Zhou XZ; Zhao TL
Cell Signal; 2018 Jan; 42():106-113. PubMed ID: 29050985
[TBL] [Abstract][Full Text] [Related]
40. BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.
Zhang Z; Ma P; Jing Y; Yan Y; Cai MC; Zhang M; Zhang S; Peng H; Ji ZL; Di W; Gu Z; Gao WQ; Zhuang G
Theranostics; 2016; 6(2):219-30. PubMed ID: 26877780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
